Eye­Gate surges on FDA nod to start piv­otal study; Alde­vron to build gene ther­a­py man­u­fac­tur­ing cam­pus in Far­go, N.D.

→ Eye­Gate — a phar­ma­ceu­ti­cal com­pa­ny spe­cial­iz­ing in de­vel­op­ing treat­ments for dis­eases and dis­or­ders of the eye — an­nounced the FDA’s ap­proval to ini­ti­ate its pho­tore­frac­tive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER